Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenalidomide in Combination With Plerixafor in Patients With Previously Treated Chronic Lymphocytic Leukemia.

Next Previous
Search
Trial Profile

Lenalidomide in Combination With Plerixafor in Patients With Previously Treated Chronic Lymphocytic Leukemia.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plerixafor (Primary) ; Lenalidomide; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions

Most Recent Events

  • 03 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 08 Feb 2015 Planned End Date changed from 1 Jun 2016 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
  • 13 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top